Two Sigma Investments
PRVB

Two Sigma Investments’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Two Sigma Investments’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-105,700
Closed -$2.55M – 3435
2023
Q1 		$2.55M Sell
105,700
-485,130
-82% -$6.09M 0.01% 1242
2022
Q4 		$6.25M Buy
590,830
+431,108
+270% +$3.48M 0.02% 755
2022
Q3 		$719K Buy
159,722
+99,995
+167% +$456K ﹤0.01% 1607
2022
Q2 		$239K Buy
59,727
+43,127
+260% +$204K ﹤0.01% 2107
2022
Q1 		$122K Buy
+16,600
New +$99.3K ﹤0.01% 2411
2021
Q4 		– Sell
-93,600
Closed -$599K – 5080
2021
Q3 		$599K Buy
93,600
+57,000
+156% +$366K ﹤0.01% 3080
2021
Q2 		$309K Sell
36,600
-500,720
-93% -$4.04M ﹤0.01% 3491
2021
Q1 		$5.64M Buy
537,320
+148,619
+38% +$2.09M 0.01% 970
2020
Q4 		$6.58M Sell
388,701
-161,631
-29% -$2.42M 0.02% 781
2020
Q3 		$7.06M Buy
550,332
+379,956
+223% +$4.8M 0.03% 639
2020
Q2 		$2.4M Buy
+170,376
New +$2.15M 0.01% 1005

Other funds holding PRVB

UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Two Sigma Investments's PRVB Position: Q2 2023 in Review

Two Sigma Investments sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 105,700 shares — an estimated $2.55M sold.

Two Sigma Investments first reported a position in PRVB in Q2 2020 and held it in 11 quarters. The position peaked at $7.06M in Q3 2020. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

  • Two Sigma Investments reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Two Sigma Investments sold 105,700 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $2.55M.
  • Two Sigma Investments first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 11 quarters.
  • Two Sigma Investments's Provention Bio, Inc. Common Stock position peaked at $7.06M in Q3 2020.
  • 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Two Sigma Investments's 13F filing for Q2 2023, filed 14 Aug 2023.